Axon Enterprise (NASDAQ:AXON) Price Target Raised to $800.00 at Robert W. Baird

Axon Enterprise (NASDAQ:AXON) had its price objective hoisted by Robert W. Baird from $600.00 to $800.00 in a research report report published on Friday morning,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

Several other brokerages also recently issued reports on AXON. Morgan Stanley upgraded shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $500.00 to $700.00 in a research note on Tuesday. The Goldman Sachs Group increased their target price on Axon Enterprise from $385.00 to $441.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. Northland Securities boosted their price target on Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. Needham & Company LLC increased their price objective on Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Finally, JMP Securities boosted their target price on Axon Enterprise from $430.00 to $500.00 and gave the stock a “market outperform” rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, Axon Enterprise currently has an average rating of “Moderate Buy” and a consensus price target of $488.67.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON opened at $687.69 on Friday. The company has a market capitalization of $52.44 billion, a PE ratio of 177.70, a PEG ratio of 15.13 and a beta of 1.01. The business has a fifty day moving average price of $516.24 and a 200-day moving average price of $392.27. Axon Enterprise has a 1-year low of $232.78 and a 1-year high of $698.67. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63.

Insider Transactions at Axon Enterprise

In related news, insider Jeffrey C. Kunins sold 8,182 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $364.86, for a total value of $2,985,284.52. Following the transaction, the insider now directly owns 176,228 shares of the company’s stock, valued at approximately $64,298,548.08. This trade represents a 4.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeri Williams sold 110 shares of the business’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $400.00, for a total value of $44,000.00. Following the sale, the director now directly owns 1,934 shares of the company’s stock, valued at $773,600. This represents a 5.38 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 137,921 shares of company stock worth $63,093,907 in the last 90 days. 6.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Axon Enterprise

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AXON. CIBC Asset Management Inc increased its stake in shares of Axon Enterprise by 9.2% in the third quarter. CIBC Asset Management Inc now owns 10,578 shares of the biotechnology company’s stock worth $4,227,000 after purchasing an additional 895 shares in the last quarter. Foundations Investment Advisors LLC purchased a new stake in Axon Enterprise in the 3rd quarter worth $221,000. Sequoia Financial Advisors LLC raised its holdings in Axon Enterprise by 4.9% during the third quarter. Sequoia Financial Advisors LLC now owns 1,727 shares of the biotechnology company’s stock valued at $690,000 after acquiring an additional 81 shares during the period. Axxcess Wealth Management LLC purchased a new position in shares of Axon Enterprise in the third quarter valued at about $814,000. Finally, Soros Capital Management LLC bought a new position in shares of Axon Enterprise in the third quarter worth about $630,000. Institutional investors own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.